Seqens and Novonesis Partner for Biocatalytic Processes in Fine Chemicals
The Seqens Group, a global manufacturer of health, personal care, and specialty ingredients, recently announced a strategic partnership with Novonesis, a sustainable biological solutions provider.
Protéus teams within Seqens have developed a long-standing expertise in enzyme discovery, optimization, and production, as well as biocatalytic process development and implementation. With the world’s largest strain bank, a broad commercial portfolio, and large-scale, state-of-the-art production facilities, Novonesis harnesses the power of enzymes to replace chemicals and metal catalysts, reduce waste, and make industrial processes greener and more efficient.
This partnership combines the expertise of both companies to offer comprehensive enzyme screening. Seqens's experience in biocatalytic processes and global manufacturing capabilities ensures the efficient delivery of process books and reaction products. Together, Seqens and Novonesis are committed to advancing biocatalysis, providing sustainable solutions, and enhancing customer value.
“This unique partnership between SEQENS and Novonesis finally brings together two industry leaders that will deliver innovative and competitive biocatalytic processes to the Fine Chemicals market,” commented Julien Boutet, Innovation & Biotechnologies Director at Seqens.
“Novonesis and Seqens, as strategic partners, will advance the Fine Chemical industry's commitment to sustainability and innovation by successfully commercializing biocatalytic concepts,” added Hans Ole Klingenberg, Vice President, Global Marketing & Strategy, House Hold Care & Industrial at Novonesis.
